ISBN: 3-540-66124-7
TITLE: The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems
AUTHOR: Kenakin, T.; Angus, J. A. (Eds.)
TOC:

Introduction: Bioassays  Past Uses and Future Potential
J.W. Black 1
Section I: Classical Pharmacology and Isolated Tissue Systems
CHAPTER 1
Human Vascular Receptors in Disease: Pharmacodynamic Analyses in Isolated Tissue
J.A. Angus. With 25 Figures 15
A. Introduction 15
B. Receptors Mediating Coronary Artery Contraction: Role in Variant Angina 16
I. Large Coronary Arteries 16
1. Ergometrine 16
2. 5-HT and Endothelium-Derived Relaxing Factor 16
II. Small Resistance Arteries 21
III. Summary and Future Work 27
C. Vascular Reactivity in Human Primary Hypertension and Congestive Heart Failure 28
I. The Technique, Function and Structure 28
II. Remodelling 29
III. Endothelial Dysfunction 31
IV. Forearm Veins in Primary Hypertension 33
V. Chronic Heart Failure 34
D. Pharmacology of Vascular Conduits for Coronary-Bypass Graft Surgery 37
I. Introduction 37
II. Internal Mammary Artery 38
III. Saphenous Vein 41
E. Human Vascular-to-Cardiac Tissue Selectivity of L- and T-Type VOCC Antagonists 41
References 47
CHAPTER 2
Problems in Assigning Mechanisms: Reconciling the Molecular and Functional Pathways in alpha-Adrenoceptor-Mediated Vasoconstriction
M.J. Lew. With 6 Figures 51
A. Introduction 51
B. Coupling Mechanisms at the Molecular and Cellular Levels 52
I. alpha_1-Adrenoceptors 52
II. alpha_2-Adrenoceptors 54
C. Coupling Mechanisms in the Intact Animal 56
D. Reconciliation 59
E. Myogenic Activation 61
F. Autocrine and Paracrine Activation 62
G. Functional Antagonism 64
H. Adenylate Cyclase and alpha_2-Adrenoceptors 66
I. Conclusions 68
References 69
CHAPTER 3
G_s Protein-Coupled Receptors in Human Heart
A.J. Kaumann. With 10 Figures 73
A. Introduction 73
B. Receptor Subtypes 73
C. beta-Adrenoceptor Subtypes 74
I. Comparison of beta_1- and beta_2-Adrenoceptors 74
1. Localisation 74
2. Function of beta_1- and beta_2-Adrenoceptors 74
3. Selective Coupling of beta_2-Adrenoceptors 75
D. Is There a Functional role for Cardiac beta_3-Adrenoceptors? 80
I. Evidence Against Cardiostimulation 80
II. Evidence for Cardiostimulation 81
III. Evidence for Cardiodepression 81
IV. Evidence Against Cardiodepression 82
E. Cardiostimulant Effects Through the Putative beta_4-Adrenoceptor 82
I. Non-Conventional Partial Agonists 82
II. The Putative beta_4-Adrenoceptor Resembles  But Is Distinct from  the beta_3-Adrenoceptor 84
III. Which Endogenous Agonist for the Putative beta_4- Adrenoceptor? 87
IV. The Putative beta_4-Adrenoceptor is a Special State of the beta_1-Adrenoceptor 88
F. 5-HAT_4 Receptors 90
I. Coupling to a cAMP Pathway 90
II. 5-HAT_4-like Receptors 91
G. Cross-Talk Between Cardiac G_s-Coupled Receptors, as Revealed by Chronic Blockade of beta_1-Adrenoceptors 95
H. Physiological, Pathophysiological and Therapeutic Relevance 101
I. beta_1- and beta_2-Adrenoceptors 101
II. Putative beta_4-Adrenoceptors 105
III. 5-HAT_4 Receptors 105
I. Epilogue 107
References 108
Section II: New Theoretical Concepts and Molecular Mechanisms of Receptor Function
CHAPTER 4
Kinetic Modeling Approaches to Understanding Ligand Efficacy
J.J. Linderman. With 19 Figures 119
A. Introduction 119
B. Background 120
I. Efficacy 120
II. Modeling 121
1. Equilibrium, Steady State, and Kinetic Models 122
2. Diffusion-Versus Reaction-Controlled Events 123
3. Model Structures and DoseResponse Curves 124
C. Parameters Contributing to Ligand Efficacy 126
I. The Lifetime of the Individual ReceptorLigand Complex (1/k_r) 126
II. The Receptor Desensitization Rate Constant k_x 131
III. The Ligand Binding and Dissociation Rate Constants at Endosomal pH 134
IV. Rate Constants in a Ternary Complex Model 139
D. Concluding Remarks 143
References 144
CHAPTER 5
The Evolution of Drug-Receptor Models: The Cubic Ternary-Complex Model for G Protein-Coupled Receptors
T. Kenakin, P. Morgan, M. Lutz, and J. Weiss. With 7 Figures 147
A. Receptor Models 147
B. The Ternary Complex Model of Receptor Function 148
C. Two-State Theory 149
D. The Extended Ternary Complex Model 151
E. The CTC Model 152
F. General Application of the Cubic Model 155
I. Evidence for the AriG Complex 158
G. Conclusion 163
References 163
CHAPTER 6
Inverse Agonism
R. Bond, G. Milligan, and M. Bouvier 167
A. Background 167
B. Overexpression, Spontaneous Activity and Inverse Agonism 168
C. Mutations and Diseases of Spontaneous Receptor Activity 173
D. Modulation of Receptor Function by Agonists and Inverse Agonists 174
E. Models 177
F. Summary and Conclusions 178
References 178
CHAPTER 7
Efficacy: Molecular Mechanisms and Operational Methods of Measurement. A New Algorithm for the Prediction of Side Effects
T. Kenakin. With 17 Figures 183
A. Introduction 183
B. The Molecular Nature of Efficacy 183
C. Positive and Negative Efficacy 186
D. The Operational Measurement of Relative Efficacy 188
I. Binding Studies 188
1. Guanosine Triphosphate gamma S Shift 188
2. High-Affinity Selection Binding 191
II. Function 192
1. The Method of Furchgott 195
2. The Method of Stephenson 196
3. Comparison of Relative Maximal Responses 197
E. Limitations of Agonist Potency Ratios 201
F. Why Measure the Relative Efficacies of Agonists? 204
G. A Simple Algorithm for the Prediction of Agonist Side Effects Using Efficacy and Affinity Estimates 206
I. Therapeutic Versus Secondary Agonism: Side Effect Versus Coupling Constant Profiles 208
II. Algorithm for Calculation of Relative beta_50 210
III. Application of the Algorithm to beta_3-Adrenoceptor Agonists 212
IV. Limitations of the Algorithm 214
H. Conclusions 215
References 215
CHAPTER 8
A Look at Receptor Efficacy. From the Signalling Network of the Cell to the Intramolecular Motion of the Receptor
H.O. Onaran, A. Scheer, S. Cotecchia, and T. Costa. With 12 Figures 217
A. Introduction 217
B. Biological Receptors and the Dualism of Affinity and Efficacy 217
I. Signal Transfer and Conformational Change in Membrane Receptor 217
II. The Distinction Between Affinity and Efficacy 218
III. Generality of the Concept of Efficacy in Functional Proteins 219
IV. Asking the Questions 219
V. Two Flavours in the Definition of Efficacy: Biological and Molecular 220
C. Biological Definitions of Efficacy 221
I. The Nature of Signal Strength 221
II. StimulusResponse Relationships 222
III. The Scale of Agonism and Antagonism 223
IV. Steps of Signal Transduction and the Indeterminacy of StimulusResponse Relationships 225
D. Molecular Definitions of Efficacy 227
I. A Molecular Link Between Affinity and Efficacy 227
II. Allosteric Equilibrium, Free-Energy Coupling, and Thermodynamic Definitions of Efficacy 227
III. Linkage Between Macroscopic Perturbations in the Receptor 231
IV. Functional and Physical States in Proteins 233
V. Microscopic Interpretation of Allosteric Equilibrium 235
E. A Stochastic Model of Molecular Efficacy 238
I. Protein Motion and Fluctuations in Its Conformational Space 238
II. Probability Distribution of Microscopic States and Derivation of Macroscopic Constants 238
III. Probabilistic Interpretation of Ligand Efficacy 241
IV. Relationship Between Physical States and Biological Function 244
V. Relationship Between Efficacy and Fluorescence Changes in b2-Adrenoceptors 244
VI. Correlated Macroscopic Changes in Constitutively Active Adrenoceptors 248
References 254
CHAPTER 9
Mechanisms of Non-Competitive Antagonism and Co-Agonism
D.G. Trist and M. Corsi. With 9 Figures 261
A. Non-Competitive Antagonism 261
I. Definition 261
II. Analysis of the Effect of Non-Competitive Antagonists 261
B. Co-Agonism 267
I. Theory as Applied to the Glutamate NMDA Receptor 267
1. Evidence for Co-Agonism 267
2. The Theory of Co-Agonism 268
3. The Effect of Competitive Antagonism on Co-Agonism 271
4. The Effect of a Non-Competitive Antagonist on the Response of Co-Agonists 273
II. Experimental Data Supporting the Concept of Co-Agonism and Its Antagonism 274
1. Recombinant Experiments 274
2. Tissue Experiments 276
III. Implications of Co-Agonism 278
C. General Observations 279
References 280
CHAPTER 10
Mechanisms of Receptor Activation and the Relationship to Receptor Structure
D.M. Perez and S.S. Karnik. With 2 Figures 283
A. Introduction 283
B. Common GPCR Structure/Function 283
C. Rhodopsin and bR Activation: Light as the Ligand 286
I. Direct Structural Information 287
II. The Activation Mechanism 288
1. How Retinal Binds 288
2. Salt-Bridge Constraining Factor: Movement of TM3 and TM6 289
D. AR Activation: Small Organics as Ligands 291
I. Important Binding Contacts of the Endogenous Ligands 291
II. Insights on How Epinephrine Activates 293
1. Release of Constraining Factors 293
2. Evidence for a Salt-Bridge as a Constraint: Movement of TM3 and TM7 294
3. Evidence for Multiple Activation States or Mechanisms 296
4. Evidence for Additional Constraining Factors: Movement of TM5 and TM6 296
E. Angiotensin-Receptor Activation: Peptides as Ligands 298
I. Peptide-Hormone GPCRs: How the Peptide Binds 298
II. The Ang-II Receptor 298
III. How AngII Peptides and Non-Peptides Bind 299
IV. Insights into AngII Activation 300
1. Role of His256 in TM6 300
2. Release of Constraining Factors: Role of TM3 300
F. The Ties that Bind: Concluding Remarks 302
I. Conservation of Critical Binding Contacts and Resulting Helical Movements 302
II. Conservation of Switches that Control Attainment of the Active State(s) 302
References 304
Section III: New Technologies for the Study of Drug Receptor Interaction
CHAPTER 11
The Assembly of Recombinant Signalling Systems and Their Use in Investigating Signaling Dynamics
S.M. Lanier. With 4 Figures 313
A. Introduction 313
B. Assembly of Recombinant Signaling Systems 314
I. Stable Transfection 314
II. Transient Expression Systems 316
C. DrugReceptor Interactions in Recombinant Signaling Systems 318
I. Cell-Type-Specific Signaling Events 318
II. Influence of Accessory Proteins 323
D. Perspective 328
References 328 
CHAPTER 12
Insect Cell Systems to Study the Communication of Mammalian Receptors and G Proteins
R.T. Windh, A.J. Barr, and D.R. Manning. With 4 Figures 335
A. Introduction 335
I. Selectivity of ReceptorG Protein Interactions 335
II. Effector Modulation as a Measure of G Protein Activity 336
III. Direct Measures of G Protein Activity 337
B. Insect Cell Expression Systems 338
I. Expression of Receptors in Insect Cell Lines 338
II. Interaction of Receptors with Endogenous G Proteins and Effectors 342
III. Quantitation of Coupling Using Radioligand Binding 343
C. Reconstitution of Mammalian Receptors and G Proteins: Reconstituted Properties of Ligand Binding 345
I. Influence of Heterotrimeric G Proteins on Binding of Agonists 346
II. Influence of Individual G Protein Subunits on Binding of Agonists 348
III. Characterization of Inverse Agonism 349
D. Reconstitution of Mammalian Receptors and G Proteins: G Protein Activation 350
I. Activation Following Co-Expression of Receptor and G Protein 350
II. Activation Following Addition of Purified G Protein to Membranes 354
III. Limitations and Technical Considerations 355
E. Conclusions 356
F. References 356
CHAPTER 13
Altering the Relative Stoichiometry of Receptors, G Proteins and Effectors: Effects on Agonist Function
G. Milligan 363
A. Introduction 363
I. Background 363
II. Systems to Modulate GPCRG ProteinEffector Stoichiometries 364
III. Cellular Distribution of Elements of G Protein-Coupled Signaling Cascades 365
B. GPCRG Protein Fusion Proteins. A Novel Means to Restrict and Define the Stoichiometry of Expression of a GPCR and a G Protein alpha Subunit 367
C. G Protein-Coupled Receptors 370
D. G_s alpha 376
E. Effector Enzymes: Adenylyl Cyclase 380
F. Conclusions 383
References 383
CHAPTER 14
The Study of DrugReceptor Interaction Using Reporter Gene Systems in Mammalian Cells
D.M. Ignar and S. Rees. With 10 Figures 391
A. Reporter Systems 391
I. What is a Reporter Gene System? 391
II. Detection Methods 391
1. Enzymatic 391
2. Non-Enzymatic 393
III. Measurement of Intracellular Signaling 393
1. Inducible Reporter Genes 393
a) Responsive Promoters 393
b) Chimeric Transcription Factors 395
2. Reporter Proteins 397
IV. Transient Versus Stable Expression of Reporter Genes 400
1. Transient Expression 400
2. Stable Expression 400
B. Use of Reporter Gene Systems in Pharmacology 401
I. Drug Discovery 401
II. Receptor Pharmacology 401
1. Use of Reporter Gene Assays to Assess Receptor Agonism 402
a) Example 1. 6CRE-Luciferase as a Reporter for G alpha_s-Coupled Receptor Signaling 402
b) Example 2. Aequorin as a Reporter for G alpha a_{q/11}-Coupled Receptor Signaling 402
c) Example 3. The Use of a Gal4/Elk-1 Chimera to Report Opioid-Receptor-Like Receptor-1 Activation of MAPK 405
2. Use of Reporter Gene Assays to Evaluate Receptor Antagonism 405
3. Simultaneous Detection of Multiple Signals 405
a) Example 1. Dual Reporter Assays 405
b) Example 2. Combination of Reporter Assays with Other Assay Types 407
4. Measurement of Constitutive Activity 409
5. Measurement of Efficacy 411
6. Assessment of New Signaling Pathways 411
References 412
CHAPTER 15
Melanophore Recombinant Receptor Systems
C.K. Jayawickreme and M.R. Lerner. With 7 Figures 415
A. Introduction 415
B. Cellular Signaling in Melanophores 417
I. Signaling Pathways 417
II. Endogenous Receptor Signaling 419
1. Melatonin 1c Receptor 421
2. alpha-Melanocyte Stimulating Hormone (MSH) Receptor 421
3. Endothelin-C Receptor 422
4. Serotonin Receptor 422
5. beta-Adrenoreceptor 422
6. VIP Receptor 423
C. Melanophore Assay Technology 423
I. Cell Culture and Related Techniques 423
1. Preparation of Cultures of Melanophore 423
2. Continuous Culturing of Xenopus laevis Melanophores 424
3. Receptor Expression 424
4. Preparation of Stable Melanophore Lines Expressing Exogenous Receptors 425
II. Signal Detection 425
1. Transmittance Reading 425
2. Digital Imaging 426
III. Screening Formats 427
1. Microtiter Well Format 427
2. Lawn Format 428
IV. Receptor Cloning and Mutagenesis Studies 428
D. Receptor Studies and Applications 429
I. Characterization of Novel GPCRs 431
II. Lawn Format Screen System 432
III. Single Transmembrane Receptors 433
IV. Receptor-Ligand Interaction Studies 434
E. Summary 435
References 435
Subject Index 441
END
